文献速递其他结缔组织病血管炎

系统性硬化症相关肺动脉高压合并间质性肺病与无间质性肺病的血流动力学治疗反应及结局比较

Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
PubMed 文献 · Arthritis Rheumatol · 2020-12-29

该研究纳入128例经右心导管确诊肺动脉高压的系统性硬化症患者(66例合并间质性肺病,62例无间质性肺病),均接受PAH靶向治疗。合并间质性肺病者基线肺血管阻力更低但一氧化碳弥散量更差,死亡率更高,且WHO功能分级改善更少;两组血流动力学改善相似,但6分钟步行距离均无改善。

要点

  • SSc-PH-ILD患者基线肺血管阻力低于SSc-PAH但DLCO更差,死亡率更高。
  • PAH靶向治疗后两组6分钟步行距离均无改善,SSc-PH-ILD的WHO功能分级改善更少。
  • 两组血流动力学改善相似,但SSc-PH-ILD临床反应差且预后更差。

核心结论

  • 间质性肺病使系统性硬化症相关肺动脉高压患者预后更差。
  • SSc-PH-ILD对PAH靶向治疗的临床反应差,但血流动力学反应与SSc-PAH无差异。

研究设计与样本

  • 多中心前瞻性注册研究,纳入15个中心128例经右心导管确诊肺动脉高压的系统性硬化症患者(66例SSc-PH-ILD,62例SSc-PAH)。
  • 所有患者接受PAH特异性治疗,胸部CT用于确认或排除间质性肺病。

主要发现

  • 基线时SSc-PH-ILD患者肺血管阻力为5.7 Wood单位,低于SSc-PAH的8.7 Wood单位(P=0.0005)。
  • 基线时SSc-PH-ILD患者一氧化碳弥散量中位数为25%(IQR 18%, 35%),低于SSc-PAH的40%(IQR 31%, 51%)(P=0.0005)。
  • SSc-PH-ILD患者1年、2年、3年死亡率分别为8.1%、21.2%、41.5%,高于SSc-PAH的4.1%、8.7%、21.4%(P=0.04)。
  • PAH靶向治疗后两组6分钟步行距离均无改善。
  • SSc-PH-ILD患者WHO功能分级改善频率为13.6%,低于SSc-PAH的33.3%(P=0.02);两组血流动力学改善相似。

临床怎么用

  • 对SSc-PH-ILD患者应认识到其预后更差且对PAH靶向治疗的临床反应有限。
  • PAH靶向治疗虽可改善血流动力学,但需关注SSc-PH-ILD患者功能状态和生存获益不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with systemic sclerosis and both pulmonary hypertension and interstitial lung disease (SSc-PH-ILD) generally carry a worse prognosis than patients with SSc and pulmonary arterial hypertension (SSc-PAH) without ILD. There is no evidence of the efficacy of PAH therapies in SSc-PH-ILD. We undertook this study to compare survival of and response to treatment in patients with SSc-PH-ILD and those with SSc-PAH. METHODS: We analyzed 128 patients (66 with SSc-PH-ILD and 62 with SSc-PAH) from 15 centers, in whom PH was diagnosed by right-sided heart catheterization; they were prospectively included in the PH registry. All patients received PAH-specific therapy. Computed tomography of the chest was used to confirm or exclude ILD. RESULTS: At baseline, patients with SSc-PH-ILD had less severe hemodynamic impairment than those with SSc-PAH (pulmonary vascular resistance 5.7 Wood units versus 8.7 Wood units; P = 0.0005) and lower diffusing capacity for carbon monoxide (median 25% [interquartile range (IQR) 18%, 35%] versus 40% [IQR 31%, 51%]; P = 0.0005). Additionally, patients with SSc-PH-ILD had increased mortality (8.1% at 1 year, 21.2% at 2 years, and 41.5% at 3 years) compared to those with SSc-PAH (4.1%, 8.7%, and 21.4%, respectively; P = 0.04). Upon treatment with PAH-targeted therapy, no improvement in the 6-minute walk distance was observed in either group. Improvement in the World Health Organization functional class was observed less frequently in patients with SSc-ILD-PH compared to those with SSc-PAH (13.6% versus 33.3%; P = 0.02). Hemodynamics improved similarly in both groups. CONCLUSION: ILD confers a worse prognosis to SSc-PH. Response to PAH-specific therapy is clinically poor in SSc-PH-ILD but was not found to be hemodynamically different from the response observed in SSc-PAH.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Chauvelot L, Gamondes D, Berthiller J, et al. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Arthritis Rheumatol. 2020. PMID: 32892515. doi:10.1002/art.41512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。